In a recent study, abemaciclib demonstrated clinical activity both alone and in combinations in women with HR+ metastatic breast cancer.
Michael J. Birrer, MD, PhD, discusses the introduction of poly ADP-ribose polymerase inhibitors to the ovarian cancer treatment landscape.
TOPAZ-1 results reveal promise for durvalumab administered in combination with gemcitabine and cisplatin to patients with advanced biliary tract cancer.
In pretreated patients with advanced small cell lung cancer, treatment with the combination of apatinib and single-agent chemotherapy showed promising efficacy and was well-tolerated, data from a prospective phase 2 study.
John F. R. Robertson, MD, discusses overall survival data from the phase II FIRST study, which looked at fulvestrant as first-line therapy for patients with advanced breast cancer.
David F. McDermott, MD, discusses methods of expanding on progress seen in the field of immunotherapy, both in the case of kidney cancer and other tumor types at the PER® European Congress on Immunotherapies in Cancer held in Barcelona.
Amultihistology basket study proved the targetability of the <em>AKT1 E17K</em> mutation in human cancers by treating patients with various types of cancer harboring an <em>AKT1 E17K </em>mutation with AZD5363, an oral pan-AKT inhibitor, according to findings published in the <em>Journal of Clinical Oncology</em>.
Dr. Strosberg discusses the safety profile and long-term toxicities of 212Pb-DOTAMTATE treatment, highlighting renal issues and achalasia in patients.
Jorge J. Castillo, MD, will explore the challenges of managing WM. He will present on September 30, 2022, at 11:04 AM.
Joseph Alvarnas, MD, Director of Medical Quality, associate clinical professor, City of Hope, discusses the treatment of HIV-associated lymphoma.